ERBB2 and breast carcinoma: The rate of Reg IV expression varied across different types of breast cancer, with rates of 61.3% (13/21) in triple-negative breast cancer (TNBC), 45.8% (22/48) in luminal type, and 71.4% (25/35) in HER-2 positive type.